COVID-19大流行期间骨质疏松诊疗的挑战与机遇
本文综述COVID-19及其治疗和疫情防控措施对骨骼健康的影响,并评估骨质疏松药物对COVID-19结局和疫苗效力的可能影响。大流行早期骨质疏松筛查率骤降而脆性骨折率基本不变,骨质疏松药物未增加COVID-19不良事件风险,应尽可能继续治疗。
要点
- 大流行早期骨质疏松筛查和骨折风险评估显著下降,脆性骨折率基本不变。
- 骨质疏松药物不增加COVID-19不良事件风险,应尽可能继续治疗。
- 维生素D缺乏与COVID-19不良结局相关,但补充能否改善结局尚不明确。
核心结论
- COVID-19大流行导致骨质疏松筛查减少和治疗中断,骨质疏松药物安全有效且应尽可能继续使用,需进一步研究大流行对长期骨骼健康的影响。
研究设计与样本
- 本文为小型综述,汇总COVID-19及其治疗和大流行本身对骨骼健康影响的现有证据,并回顾骨质疏松药物对COVID-19结局和疫苗效力的证据及专家建议。
主要发现
- 大流行早期标准骨质疏松筛查和骨折风险评估使用率急剧下降,而脆性骨折率基本不变。
- COVID-19、其治疗及公共卫生防疫措施均可能对骨骼健康产生负面影响。
- 骨质疏松治疗未已知增加COVID-19不良事件风险,临床前数据提示部分治疗可能有益。
- 维生素D缺乏明确与COVID-19不良结局相关,但补充维生素D能否改善结局尚不明确。
临床怎么用
- 应尽可能继续骨质疏松治疗,如需替换药物可参考现有建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The coronavirus disease 2019 (COVID-19) has both directly and indirectly affected osteoporosis diagnosis and treatment throughout the world. METHODS: This mini-review summarizes the available evidence regarding the effects of COVID-19, its treatment, and the consequences of the pandemic itself on bone health. Additionally, we review evidence and expert recommendations regarding putative effects of osteoporosis medications on COVID-19 outcomes and vaccine efficacy and summarize recommendations for continuation of osteoporosis treatment during the pandemic. RESULTS: The use of standard screening procedures to assess for osteoporosis and fracture risk declined dramatically early in the pandemic, while rates of fragility fractures were largely unchanged. COVID-19, its treatments, and public health measures to prevent viral spread are each likely to negatively affect bone health. Osteoporosis treatments are not known to increase risk of adverse events from COVID-19, and preclinical data suggest possible beneficial effects of some therapies. Vitamin D deficiency is clearly associated with adverse outcomes from COVID-19, but it remains unclear whether vitamin D supplementation may improve outcomes. Osteoporosis treatment should be continued whenever possible, and recommendations for substituting therapies, if required, are available. CONCLUSION: The COVID-19 pandemic has decreased screening and disrupted treatment for osteoporosis. Osteoporosis medications are safe and effective during the pandemic and should be continued whenever possible. Further studies are needed to fully understand the impact of the COVID-19 pandemic on long-term bone health.
引用
- Cromer SJ, Yu EW. Challenges and Opportunities for Osteoporosis Care During the COVID-19 Pandemic. J Clin Endocrinol Metab. 2021. PMID: 34343287. doi:10.1210/clinem/dgab570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。